20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T6859 | I-BRD9 | GSK602 | Epigenetic Reader Domain |
I-BRD9 (GSK602) is the first selective cellular inhibitor for BRD9 with pIC50 of 7.3. | |||
T13915L | PROTAC BRD9-binding moiety 1 hydrochloride | PROTAC BRD9-binding moiety 1 hydrochloride (2097512-23-5 free base) | Others |
PROTAC BRD9-binding moiety 1 hydrochloride binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC. | |||
T12560 | PROTAC BRD9 Degrader-1 | Epigenetic Reader Domain | |
PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader with IC50 of 13.5 nM. | |||
T13915 | PROTAC BRD9-binding moiety 1 | Epigenetic Reader Domain | |
PROTAC BRD9-binding moiety 1 that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC. | |||
T77975 | PROTAC BRD9 Degrader-6 | Epigenetic Reader Domain | |
PROTAC BRD9 Degrader-6, with an IC50 value of 0.13 nM, is a potent degrader of BRD9 suitable for research on BAF complex-related disorders [1]. | |||
T82821 | BRD9 Degrader-1 | Epigenetic Reader Domain | |
BRD9 Degrader-1 functions as a BRD9 degrader, demonstrating micromolar binding affinity towards BRD9 and nanomolar affinity for the ternary complex involving BRD9 and VCB [1]. | |||
T81384 | PROTAC BRD9 Degrader-3 | PROTACs | |
PROTAC BRD9 Degrader-3 is a bifunctional degrader targeting BRD9, utilized in cancer research. | |||
T81383 | PROTAC BRD9 Degrader-5 | PROTACs | |
PROTAC BRD9 Degrader-5 is a proteolysis targeting chimera (PROTAC) designed for the specific degradation of Bromodomain-containing protein 9 (BRD9). | |||
T81385 | PROTAC BRD9 Degrader-2 | PROTACs | |
PROTAC BRD9 Degrader-2 is a bifunctional compound designed for the targeted degradation of BRD9 in cancer research applications. | |||
T77936 | PROTAC BRD9 Degrader-4 | PROTACs | |
PROTAC BRD9 Degrader-4 is a bifunctional degrader targeting BRD9, designed for cancer research applications. | |||
T81382 | PROTAC BRD9 Degrader-7 | PROTACs | |
PROTAC BRD9 Degrader-7 is a selective and orally active BRD9 degrader with a DC50 of 1.02 nM and demonstrates superior pharmacokinetics, evidenced by a Cmax of 3436.95 ng/mL [1]. | |||
T74256 | PROTAC BRD9-binding moiety 5 | ||
PROTAC BRD9-binding moiety 5, a selective binder of BRD9 with an IC50 value of 4.20 μM, is utilized in PROTAC synthesis and exhibits antiproliferative activity against cancer cells [1]. | |||
T15441 | GSK8573 | Epigenetic Reader Domain | |
GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM). | |||
T31221 | DBRD9 | dBRD-9,dBRD 9 | PROTACs |
dBRD9 is a PROTAC. dBRD9 is a double-acting molecule, partially containing Bromodomain-containing protein 9 (BRD9), ligand that recruits the cereblon E3 ubiquitin ligase. Ligand that recruits the cereblon E3 ubiquitin li... | |||
T31221L | DBRD9 HCl | dBRD9 HCl(2170679-45-3 Free base) | Epigenetic Reader Domain |
dBRD9 HCl is a PROTAC composed of the BRD9 inhibitor BI 7273 conjugated to the cereblon E3 ligase ligand pomalidomide . dBRD9 HCl is a potent and selective degrader of BRD9 (IC50 = 56.6 nM in MOLM-13 cells). dBRD9 HCl do... | |||
T8342 | BRD9876 | Others , Kinesin , Microtubule Associated | |
BRD9876 is a selective inhibitor of MM1S growth. | |||
T7378 | BRD9539 | Histone Methyltransferase | |
BRD9539 is an inhibitor of euchromatin histone methyltransferase 2 (EHMT2), also known as G9a, with an IC50 value of 6.3 μM | |||
T35480 | DBRD9-A | dBRD9-A | |
Potent BRD9 degrader. Selectively binds BRD9 and elicits near complete degradation of BRD9 at nanomolar concentrations. Inhibits growth of synovial sarcoma cells in vitro and tumor progression in a synovial sarcoma xeno... | |||
T14780 | BRD9185 | Dehydrogenase | |
BRD9185 is an inhibitor of Dihydroorotate dehydrogenase (DHODH) with an EC50 of 16 nM against multidrug-resistant blood-stage parasites in vitro. | |||
T30584 | BRD9092 | BRD 9092,BRD-9092 | |
BRD9092 is an enhancer of reactive oxygen species that are nontoxic or cause genotype-selective cell death. |